1-氮杂双环[2.2.1]-3-庚酮盐酸盐 | 122737-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-氮杂双环[2.2.1]-3-庚酮盐酸盐
• 英文名称: 1-azabicyclo<2.2.1>heptan-3-one hydrochloride
• 英文别名: 1-azabicyclo[2.2.1]heptan-3-one hydrochloride；1-azabicyclo[2.2.1]heptan-3-one;hydrochloride
• CAS: 122737-66-0
• 化学式: C₆H₉NO*ClH
• mdl: MFCD21603631
• 分子量: 147.605
• InChiKey: JRRYIMFCGVGZAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.01
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  20.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-氮杂双环[2.2.1]-3-庚酮盐酸盐 在 盐酸 作用下， 以 水 为溶剂， 生成 (3S,4R)-3-hydroxy-1-azabicyclo[2.2.1]heptane-3-carboxylic acid
  参考文献：
  名称：

  与毒蕈碱激动剂AF30有关的氮杂降冰片基-螺二氧杂环戊烷的合成。

  摘要：

  已经制备了1-氮杂双环[2.2.1。]庚烷螺二氧杂环戊烷，其分子内SN 2置换的难易程度有所不同，从而在形成氟化衍生物时具有明显的差向异构体选择性。

  DOI：

  10.1016/s0040-4039(00)74693-4

文献信息

• Azabicyclic compounds, pharmaceutical compositions containing them and
  申请人：Merck Sharp & Dohme Ltd.

  公开号：US05242930A1

  公开（公告）日：1993-09-07

  Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein Q is the residue of an optionally substituted azabicyclic ring system; X represents oxa or thia; Y represents H or hydroxy; R.sup.1 and R.sup.2 independently represent phenyl or thienyl, either of which groups may be optionally substituted by halo or trifluoromethyl; R.sup.3, R.sup.4 and R.sup.5 independently represent H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, --OR.sup.a, SCH.sub.3, SOCH.sub.3, SO.sub.2 CH.sub.3, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --CO.sub.2 R.sup.a or --CONR.sup.a R.sup.b ; R.sup.a and R.sup.b independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl, are tachykinin antagonists. They and compositions thereof are therefore useful in therapy.

  化合物公式（I）及其盐和前药，其中Q是可选取代的氮杂双环环系的残基；X代表氧杂或硫杂；Y代表H或羟基；R1和R2独立地代表苯基或噻吩基，其中任一基团可以选择性地被卤素或三氟甲基取代；R3、R4和R5独立地代表H、C1-6烷基、C2-6烯基、C2-6炔基、卤素、氰基、硝基、三氟甲基、三甲基硅基、--ORa、SCH3、SOCH3、SO2CH3、--NRaRb、--NRaCORb、--NRaCO2Rb、--CO2Ra或--CONRaRb；R a和R b独立地代表H、C1-6烷基、苯基或三氟甲基，它们是缩短素拮抗剂。它们及其组合物因此在治疗中有用。
• Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0499313A1

  公开（公告）日：1992-08-19

  Compounds of formula (I), and salts and prodrugs thereof wherein    Q is the residue of an optionally substituted azabicyclic ring system;    X represents oxa or thia;    Y represents H or hydroxy;    R¹ and R² independently represent phenyl or thienyl, either of which groups may be optionally substituted by halo or trifluoromethyl;    R³, R⁴ and R⁵ independently represent H, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, -ORa, SCH₃, SOCH₃, SO₂CH₃, -NRaRb, -NRaCORb, -NRaCO₂Rb, -CO₂Ra or -CONRaRb; and    Ra and Rb independently represent H, C₁₋₆ alkyl, phenyl or trifluoromethyl,    are tachykinin antagonists. They and compositions thereof are therefore useful in therapy.

  式(I)化合物及其盐类和原药 其中 Q 是任选取代的氮杂环系统的残基； X 代表氧或硫 Y 代表 H 或羟基； R¹ 和 R² 独立地代表苯基或噻吩基，其中任一基团可任选被卤代或三氟甲基取代； R³、R⁴ 和 R⁵ 独立地代表 H、C₁₋₆ 烷基、C₂₋₆ 烯基、C₂₋₆ 炔基、卤代、氰基、硝基、三氟甲基、硝基、三氟甲基、三甲基硅基、-ORa、SCH₃、SOCH₃、SO₂CH₃、-NRaRb、-NRaCORb、-NRaCO₂Rb、-CO₂Ra 或 -CONRaRb；和 Ra 和 Rb 独立地代表 H、C₁₋₆ 烷基、苯基或三氟甲基、 是速激肽拮抗剂。因此，它们及其组合物可用于治疗。
• Synthesis of indole oxazolines, potent 5-HT3 antagonists
  作者：Christopher J Swain、Clare Kueen、Raymond Baker

  DOI：10.1016/s0040-4039(00)97385-4

  日期：1990.1
• Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)oxazoles)
  作者：C. J. Swain、R. Baker、C. Kneen、R. Herbert、J. Moseley、J. Saunders、E. M. Seward、G. I. Stevenson、M. Beer

  DOI：10.1021/jm00084a007

  日期：1992.3

  The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.
• EP2119716
  申请人：——

  公开号：——

  公开（公告）日：——